Cardiovasc Diabetol

The most recent articles from: Cardiovasc Diabetol January 2012

Cardiovasc Diabetol · Jan 2012

Meta Analysis

Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme.

This study investigated the cardiovascular (CV) safety profile of the dipeptidyl peptidase (DPP)-4 inhibitor linagliptin versus comparator treatments. ⋯ These results from a large Phase 3 programme support the hypothesis that linagliptin may have CV benefits in patients with T2DM.

read on… mark as read…

Want more great medical articles?

Keep up to date with a free trial of metajournal, personalized for your practice.
1,706,642 articles already indexed!